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diathesisTo the Editor,
We read with great interest the review article by Drs Wong Kee
SongandBaron.1 Theydiscussedbrilliantly the approach toprocedur-
ally induced bleeding, particularly during endoscopic interventions.
Patients with hemorrhagic diathesis or the anticoagulated patients
undergoing endoscopic interventions represent a further clinical
challenge. Bleeding risk associated with hemorrhagic diathesis
and tissue damage due to endoscopic intervention has increased.
Management of this clinical state is usually difﬁcult. Typical
bleeding-pronecases suchasdental extractions, colonoscopy, andco-
lon resection have been treatedusing standard hemostaticmethods.2
The authors mentioned a novel topical hemostatic agent of plant
origin, namely Ankaferd hemostat (ABS), in their review. Although
the statement about ABS is completely true, the cited reference [15]
seems to be improper.1 We would like to point out the recent
experience with ABS for the management of clinical bleeding plus
hemorrhagic diathesis.3–7 ABS affects cellular hemostasis via vital
erythrocyte aggregation and formation of a protein network with
ﬁbrinogen gamma and prothrombin.3,6 Therefore, ABS is effective in
bothbleeding individualswithnormal hemostaticparameters andpa-
tients with deﬁcient primary and/or secondary hemostasis.3,7
Controlled clinical trials indicated the safety and efﬁcacy of ABS for
the topical management of a wide variety of bleeding problems.
Cakarer and coworkers5 disclosed thehemostatic effects of ABSduring
dental extractions in patients on antithrombotic therapy. Likewise,
ABS is a very useful agent for the management of gastrointestinal
bleeding and many other symptoms with or without bleeding diath-
esis.3–7 The ability of ABS to induce the formation of a protein network
not only makes it an effective hemostatic agent, but also confers anti-
infective, antineoplastic, and healing modulator properties to the
extract. Future controlled studies are needed to shed further light on
theexpanding spectrumofABSeffects inhemostasis and relatedareas.
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http://dx.doi.org/10.1016/j.gii.2013.09.001Response to letter “Topical
Ankaferd hemostat for the
management of clinical
bleeding plus hemorrhagic
diathesis” by Purnak et al.
We appreciate the interest of Purnak et al. regarding our manu-
script on managing procedure-related bleeding.1 We agree that
bleeding in the setting of underlying bleeding diathesis is particu-
larly difﬁcult to manage and also appreciate the insight into the
use of the ankaferd hemostat (ABS) as a topical therapy in this
setting. Unfortunately, this agent is not available to all endoscopists
